- In April 2024, Thermo Fisher Scientific announced the expansion of its St. Louis biologics facility with new single-use bioreactor lines specifically designed for vaccine and viral vector production. This strategic investment enhances the company’s global capacity to support both clinical and commercial vaccine manufacturing, underscoring its commitment to scalable, flexible solutions that accelerate time-to-market and reduce contamination risks in biologics production
- In March 2024, Cytiva launched the Xcellerex XDR-50 MO, a next-generation modular single-use bioreactor designed to streamline upstream processing for vaccine production. With improved process control and automation features, this system is aimed at supporting both research-scale and GMP-compliant vaccine manufacturing. The innovation reinforces Cytiva’s position as a key enabler of rapid, reliable bioproduction technologies
- In February 2024, Merck KGaA, Darmstadt, Germany (operating as MilliporeSigma in the U.S. and Canada), opened a new single-use manufacturing center in Molsheim, France. This facility focuses on producing single-use assemblies and bioreactors used in vaccine development and biopharmaceutical applications. The move addresses the increasing global demand for disposable bioprocessing tools, especially in pandemic preparedness and routine immunization programs
- In January 2024, Sartorius expanded its product portfolio with the introduction of the BIOSTAT STR® Generation 4 single-use bioreactor system, featuring enhanced digital integration, AI-assisted analytics, and advanced automation. Tailored for vaccine developers, this system is designed to optimize cell culture performance and reduce process variability, aligning with industry needs for precision and speed in biologics manufacturing
- In December 2023, ABEC, a global supplier of integrated solutions for biopharmaceutical manufacturing, completed the installation of custom single-use bioreactor systems for a leading vaccine developer in Southeast Asia. This project supports localized vaccine production and demonstrates ABEC’s flexibility in delivering scalable single-use solutions for emerging markets, reinforcing its global reach and adaptability to client-specific manufacturing goals
